NCT07056673 Cold Atmospheric Plasma for Moderate-to-severe Acne Vulgaris Study
| NCT ID | NCT07056673 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Shenyang Medical College |
| Condition | Acne Vulgaris |
| Study Type | INTERVENTIONAL |
| Enrollment | 220 participants |
| Start Date | 2025-07-26 |
| Primary Completion | 2026-07-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 220 participants in total. It began in 2025-07-26 with a primary completion date of 2026-07-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Acne vulgaris is a common, chronic inflammatory skin disease with complex pathogenesis and limited therapeutic options, especially for moderate-to-severe cases. Standard treatments-including topical and oral agents-are often constrained by side effects, antimicrobial resistance, and treatment resistance. Cold atmospheric plasma (CAP), a novel technology that generates reactive oxygen and nitrogen species, has demonstrated antimicrobial and tissue-regenerative properties in dermatology, but robust clinical evidence in acne management remains scarce. Existing data suggest promising efficacy and safety, yet its use in moderate-to-severe acne vulgaris has not been adequately investigated. This study aims to evaluate the efficacy and safety of two self-developed CAP devices as a potential innovative therapy for moderate-to-severe acne vulgaris.
Eligibility Criteria
Inclusion Criteria: * Aged 18-40 years; * Clinically diagnosed with acne vulgaris, with moderate to severe disease (Pillsbury grade III or IV, lesion count ≥50); * Will agree to use effective contraception during the treatment period; * Will sign a written informed consent form. Exclusion Criteria: * Pregnant or breastfeeding women; * Known allergy to any active component of CAP; * Use of systemic antibiotics within 4 weeks prior to enrollment; * Presence of dyslipidemia or other severe systemic diseases; * Participation in other clinical trials within the past 3 months or currently enrolled in another clinical trial.
Contact & Investigator
Lin Tao, MM
PRINCIPAL INVESTIGATOR
Shenyang Medical College
Frequently Asked Questions
Who can join the NCT07056673 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 40 Years, studying Acne Vulgaris. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07056673 currently recruiting?
Yes, NCT07056673 is actively recruiting participants. Contact the research team at lye9901@163.com for enrollment information.
Where is the NCT07056673 trial being conducted?
This trial is being conducted at Luoyang, China.
Who is sponsoring the NCT07056673 clinical trial?
NCT07056673 is sponsored by Shenyang Medical College. The principal investigator is Lin Tao, MM at Shenyang Medical College. The trial plans to enroll 220 participants.